A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Stopped Based on data collected, the combination appeared to be poorly tolearated.
Conditions
Interventions
- DRUG: bevacizumab
- DRUG: sunitinib
- DRUG: paclitaxel
Sponsor
Genentech, Inc.